Stockscreener 앱 받기
43.73
0.27%
-0.12
시간 외 거래:
43.73
전일 마감가:
$43.85
열려 있는:
$43.33
하루 거래량:
850.19K
Relative Volume:
2.13
시가총액:
$1.87B
수익:
$384.90M
순이익/손실:
$-851.00K
주가수익비율:
-2,186.50
EPS:
-0.02
순현금흐름:
$12.83M
1주 성능:
+35.51%
1개월 성능:
+39.00%
6개월 성능:
+45.09%
1년 성능:
+74.36%
1일 변동 폭
$42.27
$43.97
1주일 범위
$32.15
$43.97
52주 변동 폭
$21.97
$43.97
Artivion Inc Stock (AORT) Company Profile
명칭
Artivion Inc
전화
(770) 419-3355
주소
1655 ROBERTS BOULEVARD N W, KENNESAW
AORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
43.73 | 2.07B | 384.90M | -851.00K | 12.83M | -0.02 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Canaccord Genuity | Buy |
| 2024-10-23 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-27 | 재확인 | Lake Street | Buy |
| 2022-08-08 | 개시 | Lake Street | Buy |
| 2022-03-03 | 개시 | Stifel | Buy |
Artivion Inc 주식(AORT)의 최신 뉴스
Artivion stock hits 52-week high at 43.93 USD By Investing.com - Investing.com Australia
Artivion at Canaccord Conference: Strategic Growth and Innovation - Investing.com
Artivion's (AORT) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Can Artivion Inc. ride the EV wavePositive Outlook Long-Term Picks - kangso.co.kr
Revenues Tell The Story For Artivion, Inc. (NYSE:AORT) As Its Stock Soars 37% - simplywall.st
Artivion, Inc. (NYSE:AORT) Q2 2025 Earnings Call Transcript - Insider Monkey
Artivion Inc. Reports Strong Q2 Earnings and Positive Outlook - TipRanks
Artivion Appoints Lance Berry as COO, Raises Earnings Guidance - AInvest
Artivion Appoints Lance Berry as COO - MarketScreener
Artivion Appoints Lance A. Berry as COO - TipRanks
Artivion Reaches Analyst Target Price - Nasdaq
Artivion Shows Market Leadership With Jump To 93 RS Rating - Investor's Business Daily
Artivion Surges on Improved 2025 Financial Outlook - StocksToTrade
Artivion’s Stocks Surge as Q2 Financials Exceed Expectations - timothysykes.com
Canaccord Genuity Group Forecasts Strong Price Appreciation for Artivion (NYSE:AORT) Stock - Defense World
What technical models suggest about Artivion Inc.’s comebackPredictive Short-Term Market Reversal Alerts - Newser
Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth - MSN
Artivion's Q2 Earnings Surge: A High-Margin Medical Innovation Play with Undervalued Potential - AInvest
Artivion, Inc.'s (NYSE:AORT) 26% Jump Shows Its Popularity With Investors - 富途牛牛
Artivion price target raised to $45 from $32 at Needham - Yahoo Finance
Artivion Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com
Artivion Elevates 2025 Revenue Projection Amid Strong Q2 Earnings - StocksToTrade
A Quick Look at Today's Ratings for Artivion(AORT.US), With a Forecast Between $40 to $45 - 富途牛牛
Artivion 2025 Q2 Earnings Strong Performance with Net Income Surges 163% - AInvest
Artivion price target raised to $41 from $35 at Canaccord - MSN
Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Artivion, Inc. (NYSE:AORT) - Defense World
Artivion (NYSE:AORT) Shares Gap Up on Better-Than-Expected Earnings - Defense World
Is Artivion Inc. stock heavily shortedBest ROI Stock Strategies - thegnnews.com
Artivion (NYSE:AORT) Stock Rating Upgraded by Wall Street Zen - Defense World
Comparing Artivion Inc. in custom built stock radarsSector-Wise Equity Performance Trend Forecast - Newser
Artivion Inc. stock trend forecastFree Swing Trading Entry Point Signals - Newser
Artivion (AORT): Canaccord Genuity Raises Price Target to $41.00 - GuruFocus
Artivion: Canaccord Genuity Raises PT to $41 from $35, Maintains Buy Rating - AInvest
Artivion’s Surging Stock: Rising Star or Temporary Miracle? - timothysykes.com
A Quick Look at Today's Ratings for Artivion(AORT.US), With a Forecast Between $35 to $45 - 富途牛牛
Artivion (AORT): Accelerating Growth and Margin Expansion in a High-Margin Medical Device Niche - AInvest
Artivion Raises 2025 Revenue Guidance to $435M-$443M, Driven by On-X and Stent Grafts. - AInvest
Why Is Artivion (AORT) Stock Rocketing Higher Today - Yahoo Finance
Artivion: JMP Securities Raises PT to $42 from $33, Maintains Market Outperform - AInvest
ARTIVION, INC. SEC 10-Q Report - TradingView
Artivion stock price target raised by Stifel to $40 on strong AMDS launch - Investing.com Nigeria
Stifel Raises Artivion's PT to $40, Maintains Buy Rating - AInvest
Needham raises Artivion stock price target to $45 on growth acceleration - Investing.com Australia
Artivion Exceeds Q2 Revenue Estimates, Stock Jumps 13.1% - AInvest
Artivion: Needham Keeps Buy Rating, Raises PT to $45 from $32 - AInvest
High Insider Ownership and Revenue Growth: Top US Growth Companies - AInvest
Artivion stock price target raised to $41 from $35 at Canaccord on strong Q2 - Investing.com UK
Artivion price target raised to $42 from $33 at Citizens JMP - TipRanks
Oppenheimer raises Artivion stock price target to $40 on strong Q2 results - Investing.com Canada
Artivion revenue up 15% to USD 113M in Q2 2025 - Medical Buyer
Oppenheimer lowers Artivion stock price target to $40 from $42, maintains Outperform By Investing.com - Investing.com South Africa
Artivion Inc (AORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.31%
1.36%
자본화:
|
볼륨(24시간):